D E Freedberg1, K Haynes2, M R Denburg3, B S Zemel4, M B Leonard5, J A Abrams6, Y-X Yang2,7. 1. Division of Digestive and Liver Diseases, Columbia University Medical Center, 630 West 168th Street, PH-7, New York, NY, 10032, USA. def2004@cumc.columbia.edu. 2. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. 3. Division of Nephrology, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA. 4. Department of Pediatrics, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. 5. Departments of Medicine and Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA. 6. Division of Digestive and Liver Diseases, Columbia University Medical Center, 630 West 168th Street, PH-7, New York, NY, 10032, USA. 7. Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Abstract
UNLABELLED: Proton pump inhibitors (PPIs) are associated with risk for fracture in osteoporotic adults. In this population-based study, we found a significant association between PPIs and fracture in young adults, with evidence of a dose-response effect. Young adults who use PPIs should be cautioned regarding risk for fracture. INTRODUCTION: Proton pump inhibitors (PPIs) are associated with fracture in adults with osteoporosis. Because PPI therapy may interfere with bone accrual and attainment of peak bone mineral density, we studied the association between use of PPIs and fracture in children and young adults. METHODS: We conducted a population-based, case-control study nested within records from general medical practices from 1994 to 2013. Participants were 4-29 years old with ≥ 1 year of follow-up who lacked chronic conditions associated with use of long-term acid suppression. Cases of fracture were defined as the first incident fracture at any site. Using incidence density sampling, cases were matched with up to five controls by age, sex, medical practice, and start of follow-up. PPI exposure was defined as 180 or more cumulative doses of PPIs. Conditional logistic regression was used to estimate the odds ratio and confidence interval for use of PPIs and fracture. RESULTS: We identified 124,799 cases and 605,643 controls. The adjusted odds ratio for the risk of fracture associated with PPI exposure was 1.13 (95% CI 0.92 to 1.39) among children aged < 18 years old and 1.39 (95% CI 1.26 to 1.53) among young adults aged 18-29 years old. In young adults but not children, we observed a dose-response effect with increased total exposure to PPIs (p for trend <0.001). CONCLUSIONS: PPI use was associated with fracture in young adults, but overall evidence did not support a PPI-fracture relationship in children. Young adults who use PPIs should be cautioned regarding potentially increased risk for fracture, even if they lack traditional fracture risk factors.
UNLABELLED: Proton pump inhibitors (PPIs) are associated with risk for fracture in osteoporotic adults. In this population-based study, we found a significant association between PPIs and fracture in young adults, with evidence of a dose-response effect. Young adults who use PPIs should be cautioned regarding risk for fracture. INTRODUCTION:Proton pump inhibitors (PPIs) are associated with fracture in adults with osteoporosis. Because PPI therapy may interfere with bone accrual and attainment of peak bone mineral density, we studied the association between use of PPIs and fracture in children and young adults. METHODS: We conducted a population-based, case-control study nested within records from general medical practices from 1994 to 2013. Participants were 4-29 years old with ≥ 1 year of follow-up who lacked chronic conditions associated with use of long-term acid suppression. Cases of fracture were defined as the first incident fracture at any site. Using incidence density sampling, cases were matched with up to five controls by age, sex, medical practice, and start of follow-up. PPI exposure was defined as 180 or more cumulative doses of PPIs. Conditional logistic regression was used to estimate the odds ratio and confidence interval for use of PPIs and fracture. RESULTS: We identified 124,799 cases and 605,643 controls. The adjusted odds ratio for the risk of fracture associated with PPI exposure was 1.13 (95% CI 0.92 to 1.39) among children aged < 18 years old and 1.39 (95% CI 1.26 to 1.53) among young adults aged 18-29 years old. In young adults but not children, we observed a dose-response effect with increased total exposure to PPIs (p for trend <0.001). CONCLUSIONS: PPI use was associated with fracture in young adults, but overall evidence did not support a PPI-fracture relationship in children. Young adults who use PPIs should be cautioned regarding potentially increased risk for fracture, even if they lack traditional fracture risk factors.
Entities:
Keywords:
Acid suppression medications; Bone mineral density; Fracture; Histamine-2 receptor antagonists; Osteoporosis; Outcomes research; Pediatrics; Pharmacoepidemiology; Proton pump inhibitors
Authors: Shelly L Gray; Andrea Z LaCroix; Joseph Larson; John Robbins; Jane A Cauley; JoAnn E Manson; Zhao Chen Journal: Arch Intern Med Date: 2010-05-10
Authors: James D Lewis; Rita Schinnar; Warren B Bilker; Xingmei Wang; Brian L Strom Journal: Pharmacoepidemiol Drug Saf Date: 2007-04 Impact factor: 2.890
Authors: Daniel R Duncan; Janine Amirault; Paul D Mitchell; Kara Larson; Rachel L Rosen Journal: J Pediatr Gastroenterol Nutr Date: 2017-08 Impact factor: 2.839
Authors: Ann M Neumeyer; Natalia Cano Sokoloff; Erin McDonnell; Eric A Macklin; Christopher J McDougle; Madhusmita Misra Journal: J Pediatr Date: 2016-11-22 Impact factor: 4.406
Authors: Naomi R M Schwartz; Susan Hutfless; Lisa J Herrinton; Laura B Amsden; Helene B Fevrier; Matthew Giefer; Dale Lee; David L Suskind; Joseph A C Delaney; Amanda I Phipps Journal: J Pediatr Pharmacol Ther Date: 2019 Nov-Dec
Authors: Yun-Han Wang; Viktor Wintzell; Jonas F Ludvigsson; Henrik Svanström; Björn Pasternak Journal: JAMA Pediatr Date: 2020-06-01 Impact factor: 16.193